Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Accumulated Depreciation (2024 - 2025)

Maze Therapeutics' Accumulated Depreciation history spans 2 years, with the latest figure at $19.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 13.9% to $19.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.2 million, a 13.9% increase, with the full-year FY2025 number at $19.2 million, up 13.9% from a year prior.
  • Accumulated Depreciation hit $19.2 million in Q4 2025 for Maze Therapeutics, up from $16.9 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for MAZE hit a ceiling of $19.2 million in Q4 2025 and a floor of $16.9 million in Q4 2024.